HIGHLIGHTS
- who: ARNi Angiotensin Receptor-neprilysin Inhibitor et al. from the Larkin Community Hospital, Miami, Florida, USA University of Carabobo, Venezuela have published the article: Heart Failure Management, including Recently Approved Therapeutic Options: An Overview, in the Journal: (JOURNAL)
- what: This trial showed a significant reduction in all causes of death in the spironolactone group compared to placebo .
- future: The exact mechanisms are unknown and further studies are required.
SUMMARY
Globally, heart failure (HF) is one of the significant causes of morbidity and mortality, and it is considered a complex . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.